Actively Recruiting
Open-Label Study Evaluating Multiple Ascending Doses of OM336 via Subcutaneous Injection in Adults With Active Autoimmune Cytopenias
Led by Lakefront Biotherapeutics West LLC · Updated on 2026-09-03
32
Participants Needed
7
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating OM336, an engineered bispecific antibody targeting BCMA and CD3, in adult participants with active autoimmune cytopenias, including warm and cold autoimmune hemolytic anemia and immune thrombocytopenia. This early-phase, open-label, multicenter study focuses on assessing the safety, tolerability, and pharmacokinetics of OM336 administered subcutaneously in ascending dose cohorts. Participants will receive OM336 through subcutaneous injections in increasing doses to evaluate its effects. The study includes multiple dose escalation groups to monitor how participants respond to the treatment over time. The primary treatment period lasts 12 weeks, with additional safety and tolerability assessments extending to 52 weeks to closely observe longer-term effects. During the study, participants will be monitored for safety and tolerability through regular assessments, including pharmacokinetic measurements and tests for anti-drug antibodies. The research team will track participant responses over the course of treatment and follow-up visits. The total participation may last up to 52 weeks, allowing detailed evaluation of both immediate and sustained effects of OM336.
CONDITIONS
Brief Title
OM336 in Autoimmune Cytopenias
Research Team
S
Study Sponsor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here